This builds on a substantial body of evidence from earlier trials, including CheckMate 816 and NADIM. In CheckMate 816, ctDNA clearance rates were 56% with nivolumab plus chemotherapy versus 35% with chemotherapy alone, and clearance was strongly associated with pCR and longer survival . A recent analysis of CheckMate 77T also showed that ctDNA clearance was associated with improved EFS, with a hazard ratio of 0.38 (95% CI, 0.16-0.88) for patients who cleared ctDNA . Across multiple studies, ctDNA clearance before surgery has consistently been linked to higher rates of major pathological response .

Addressing the Challenge of Overtreatment

While perioperative nivolumab improves outcomes for many patients, a significant number derive no benefit yet remain at risk for immunotherapy-related toxicities and financial burden . The new findings address this in several ways:

• Sparing non-responders: Patients who do not clear ctDNA after neoadjuvant therapy can be identified early and potentially spared the full perioperative course, avoiding severe immune-related adverse events (irAEs) and futile continuation of treatment .

• Cost avoidance: With a course of perioperative nivolumab costing well over $150,000, using ctDNA clearance as a real-time decision tool could stop ineffective therapy early, generating substantial savings for patients and healthcare systems . The biomarker approach enables resources to be directed only to those most likely to benefit.

• Reducing toxicity: Immunotherapy can cause serious autoimmune side effects. By identifying non-responders early, clinicians can avoid exposing them to these risks without compromising outcomes .

Moving Beyond PD-L1 Expression

The study represents a shift from relying solely on PD-L1 expression—the current standard but imperfect biomarker—toward truly individualized molecular surveillance . While PD-L1 remains a useful predictive biomarker, it is insufficient alone to guide perioperative immunotherapy decisions, particularly since the FDA approved perioperative nivolumab without a PD-L1 restriction .

The August 2026 study employs a tumor-informed, personalized ctDNA monitoring platform that tracks each patient's unique mutational signature . This allows ctDNA dynamics to function as a liquid biopsy "on/off switch" tailored to the patient's specific tumor genome, enabling adaptive treatment de-escalation and escalation in the perioperative setting .

Broader Context and Corroborating Evidence

This research aligns with findings from multiple major trials:

• CheckMate 816: ctDNA clearance after neoadjuvant nivolumab plus chemotherapy predicted improved EFS and OS, outperforming radiologic assessments .
• CheckMate 77T: Perioperative nivolumab showed significant EFS benefit (HR 0.58; P < 0.001) in stage II-IIIB NSCLC, with ctDNA analysis showing that clearance was associated with the greatest benefit .
• NADIM: 5-year follow-up showed 65.0% progression-free survival and 69.3% overall survival with perioperative chemoimmunotherapy, with ctDNA clearance correlating with improved outcomes .

Important Caveat

The analysis available here is based primarily on MD Anderson's press release and supportive data from prior trials . The full peer-reviewed manuscript in Nature Medicine was not fully retrieved; a complete evaluation of its statistical rigor, biomarker thresholds, and validation cohorts would require accessing the full publication. However, the conclusion is directionally consistent with prior ctDNA analyses, which strongly support the predictive value of ctDNA clearance for pathologic response and survival .

This builds on a substantial body of evidence from earlier trials, including CheckMate 816 and NADIM. In CheckMate 816, ctDNA clearance rates were 56% with nivolumab plus chemotherapy versus 35% with chemotherapy alone, and clearance was strongly associated with pCR and longer survival . A recent analysis of CheckMate 77T also showed that ctDNA clearance was associated with improved EFS, with a hazard ratio of 0.38 (95% CI, 0.16-0.88) for patients who cleared ctDNA . Across multiple studies, ctDNA clearance before surgery has consistently been linked to higher rates of major pathological response .

Addressing the Challenge of Overtreatment

While perioperative nivolumab improves outcomes for many patients, a significant number derive no benefit yet remain at risk for immunotherapy-related toxicities and financial burden . The new findings address this in several ways:

• Sparing non-responders: Patients who do not clear ctDNA after neoadjuvant therapy can be identified early and potentially spared the full perioperative course, avoiding severe immune-related adverse events (irAEs) and futile continuation of treatment .

• Cost avoidance: With a course of perioperative nivolumab costing well over $150,000, using ctDNA clearance as a real-time decision tool could stop ineffective therapy early, generating substantial savings for patients and healthcare systems . The biomarker approach enables resources to be directed only to those most likely to benefit.

• Reducing toxicity: Immunotherapy can cause serious autoimmune side effects. By identifying non-responders early, clinicians can avoid exposing them to these risks without compromising outcomes .

Moving Beyond PD-L1 Expression

The study represents a shift from relying solely on PD-L1 expression—the current standard but imperfect biomarker—toward truly individualized molecular surveillance . While PD-L1 remains a useful predictive biomarker, it is insufficient alone to guide perioperative immunotherapy decisions, particularly since the FDA approved perioperative nivolumab without a PD-L1 restriction .

The August 2026 study employs a tumor-informed, personalized ctDNA monitoring platform that tracks each patient's unique mutational signature . This allows ctDNA dynamics to function as a liquid biopsy "on/off switch" tailored to the patient's specific tumor genome, enabling adaptive treatment de-escalation and escalation in the perioperative setting .

Broader Context and Corroborating Evidence

This research aligns with findings from multiple major trials:

• CheckMate 816: ctDNA clearance after neoadjuvant nivolumab plus chemotherapy predicted improved EFS and OS, outperforming radiologic assessments .
• CheckMate 77T: Perioperative nivolumab showed significant EFS benefit (HR 0.58; P < 0.001) in stage II-IIIB NSCLC, with ctDNA analysis showing that clearance was associated with the greatest benefit .
• NADIM: 5-year follow-up showed 65.0% progression-free survival and 69.3% overall survival with perioperative chemoimmunotherapy, with ctDNA clearance correlating with improved outcomes .

Important Caveat

The analysis available here is based primarily on MD Anderson's press release and supportive data from prior trials . The full peer-reviewed manuscript in Nature Medicine was not fully retrieved; a complete evaluation of its statistical rigor, biomarker thresholds, and validation cohorts would require accessing the full publication. However, the conclusion is directionally consistent with prior ctDNA analyses, which strongly support the predictive value of ctDNA clearance for pathologic response and survival .